Маркеры опухолевого роста в диагностике рака почки

Маркеры опухолевого роста в диагностике рака почки

Автор: Баныра О.Б., Строй А.А., Шуляк А.В.

Журнал: Экспериментальная и клиническая урология @ecuro

Рубрика: Онкоурология

Статья в выпуске: 4, 2011 года.

Бесплатный доступ

Рак почки, маркеры опухолевого роста, тканевые биомаркеры, маркеры крови, маркеры мочи, биомаркеры раннего выявления, диагностические биомаркеры, биомаркеры предсказания

Короткий адрес: https://sciup.org/142188278

IDR: 142188278

Список литературы Маркеры опухолевого роста в диагностике рака почки

  • Rini B., Small E. Biology and Clinical Development of Vascular Endothelial Growth Factor-Targeted Therapy in Renal Cell Carcinoma//Journal of Clinical Oncology, 2005; Vol. 23 (5): P. 1028-1043.
  • Баныра О.Б., Шуляк А.В., Ингибиция ангиогенеза в лечении рака почки: механизмы, особенности и перспективы//Экспериментальная и клиническая урология, 2011; Т.1: С. 59-68.
  • Rini B.I., Cohen D.P., Lu D., et al. Hypertension (HTN) as a biomarker of efficacy in patients (pts) with metastatic renal cell carcinoma (mRCC) treated with sunitinib 2010 Genitourinary Cancers Symposium//2010, abstr 312.
  • Harzstark A.L., Halabi S., Stadler W.M., et al. Hypertension is associated with clinical outcome for patients(pts) with metastatic renal cell carcinoma (RCC) treated with interferon and bevacizumab on CALGB 90206. 2010 Genitourinary Cancer Symposium//2010, abstr. 351.
  • Choueiri T.K., Xie W., Kollmannsberger C.K., et al. The impact of body mass index (BMI) and body surface area (BSA) on treatment outcome to vascular endothelial growth factor (VEGF)-targeted therapy in metastatic renal cell carcinoma: Results from a large international collaboration//J Clin Oncol. 2010; 28:15s (suppl; abstr. 4524).
  • Li M. and Rathmell W.K. The Current Status of Biomarkers for Renal Cell Carcinoma//2011, P. 153-157 awaliable at: http: www.asco.org/ASCOv2/Home/Education.
  • Brauch H., Weirich G., Brieger J., Glavac D., Rödl H., Eichinger M., Feurer M., Weidt E., Puranakanitstha C., Neuhaus C., Pomer S., Brenner W., Schirmacher P., Störkel S., Rotter M., Masera A., Gugeler N., Decker H.J. VHL alterations in human clear cell renal cell carcinoma: association with advanced tumor stage and a novel hot spot mutation//Cancer Res. 2000 Apr 1;60(7):1942-8.
  • Gad S., Sultan-Amar V., Meric J., et al. Somatic von Hippel-Lindau (VHL) gene analysis and clinical outcome under antiangiogenic treatment in metastatic renal cell carcinoma: Preliminary results//Targeted Oncol. 2007; 2:3-6.
  • Hutson T.E., Davis I.D., Macheils J.H., et al. Biomarker analysis and final efficacy and safety results of a phase II renal cell carcinoma trial with pazopanib (GW786034), a multikinase angiogenesis inhibitor//J Clin Oncol. 2008; 26;15s (suppl; abstr 5046).
  • Wehler Th.C., Graf C., Biesterfeld S. et al. Strong expression of chemokine receptor CXCR4 by renal cell carcinoma correlates with advanced disease//Journal of Oncology, 2008, Vol. 1. Hindawi Publishing Corporation, Sep. 29, 2008.
  • DAlterio C., Cindolo L., Portella L., Polimeno M., Consales C., Riccio A., Cioffi M., Franco R., Chiodini P., Carteni G., Mirone V., Longo N., Marra L., Perdona S., Claudio L., Mascolo M., Staibano S., Falsaperla M., Puglisi M., Martignoni G., Ficarra V., Castello G., Scala S. Differential role of CD133 and CXCR4 in renal cell carcinoma//Cell Cycle. 2010 Nov 15;9(22):4492-4500.
  • Shariat S., Karakiewcz P., Godoy G. et al. Survivin as a prognostic marker for urothelial carcinoma of the bladder: a multicenter external validation study//Clinical Cancer Research. 2009; 15(22):7012-9.
  • Shariat S., Lotan Y., Saboorian H. et al. Survivin expression is associated with features of biologically aggressive prostate carcinoma//Cancer. 2004; 100(4):751-7.
  • Mahotka C., Krieg T., Krieg A. et al. Distinct in vivo expression patterns of survivin splice variants in renal cell carcinomas//Int J Cancer. 2002 Jul 1; 100(1):30-6.
  • Zamparese R., Pannone G., Santoro A. et al. Survivin expression in renal cell carcinoma//Cancer Invest. 2008 Nov 1; 26(9):929-35.
  • Velickovic M., Delahunt B., McIver B., Grebe S.K.G. Intragenic PTEN/MMAC1 loss of heterozygosity in conventional (clear-cell) renal cell carcinoma is associated with poor patient prognosis//Mod Pathol. 2002 May 1; 15(5): 479-85
  • Pantuck A.J., Seligson D.B., Klatte T., et al. Prognostic relevance of the mTOR pathway in renal cell carcinoma: Implications for molecular patient selection for targeted therapy//Cancer. 2007; 109: 2257-2267.
  • Figlin R.A., de Souza P., McDermott D. et al. Analysis of PTEN and HIF-1alpha and correlation with efficacy in patients with advanced renal cell carcinoma treated with temsirolimus versus interferon-alpha//Cancer. 2009; 115: 3651-3660.
  • Youssif T.A., Fahmy M.A., Koumakpayi I.H., et al. The mammalian target of rapamy-cin pathway is widely activated without PTEN deletion in renal cell carcinoma metas-tases//Cancer. 2010; 117: 290-300.
  • Cho D., Signoretti S., Dabora S. et al. Potential histologic and molecular predictors of response to temsirolimus in patients with advanced renal cell carcinoma//Clin Genitourin Cancer. 2007; 5: 379-385.
  • Hehlgans S., Cordes N. Caveolin-1: an essential modulator of cancer cell radio-and chemoresistance//Am J Cancer Res 2011; 1(4): 521-530.
  • Campbell L., Jasani B., Edwards K., Gumbleton M., Griffiths D.F.R. Combined expression of caveolin-1 and an activated AKT/mTOR pathway predicts reduced disease-free survival in clinically confined renal cell carcinoma//Br J Cancer. 2008 Mar 11; 98(5): 931-40.
  • Parisi F., González A.M., Nadler Y, Camp R.L., Rimm D.L., Kluger H.M. and Kluger Y. Benefits of biomarker selection and clinico-pathological covariate inclusion in breast cancer prognostic models//Breast Cancer Res. 2010; 12(5): R66. Published online 2010 September 1 DOI: 10.1186/bcr2633
  • Rini B.I., Zhou M., Aydin H., et al. Identification of prognostic genomic markers in patients with localized clear cell renal cell carcinoma (ccRCC)//J Clin Oncol. 2010; 28:15s (suppl; abstr. 4501).
  • Rioux-Leclercq N., Fergelot P., Zerrouki S, et al. Plasma level and tissue expression of vascular endothelial growth factor in renal cell carcinoma: a prospective study of 50 cases//Hum Pathol. 2007 Oct 1; 38(10):1489-95.
  • Negrier S., Perol D., Menetrier-Caux C., et al. Interleukin-6, interleukin-10, and vascular endothelial growth factor in metastatic renal cell carcinoma: prognostic value of interleukin-6 from the Groupe Francais d'Immunotherapie//J Clin Oncol. 2004 Jun 15; 22(12): 2371-8.
  • Schips L., Dalpiaz O., Lipsky K., et al. Serum levels of vascular endothelial growth factor (VEGF) and endostatin in renal cell carcinoma patients compared to a control group//Eur Urol. 2007 Jan 1; 51(1):168-73; discussion 74.
  • Shariat S., Anwuri V., Lamb D., et al. Association of preoperative plasma levels of vascular endothelial growth factor and soluble vascular cell adhesion molecule-1 with lymph node status and biochemical progression after radical prostatectomy//J Clin Oncol. 2004; 22(9):1655-63.
  • Deprimo S.E., Bello C.L., Smeraglia J., et al. Circulating protein biomarkers of pharmacodynamic activity of sunitinib in patients with metastatic renal cell carcinoma: Modulation of VEGF and VEGF-related proteins//J Transl Med. 2007; 5:32.
  • Hutson T.E., Davis I.D., Macheils J.H., et al. Biomarker analysis and final efficacy and safety results of a phase II renal cell carcinoma trial with pazopanib (GW786034), a multikinase angiogenesis inhibitor//J Clin Oncol. 2008; 26; 15s (suppl; abstr 5046).
  • Bukowski R.M., Eisen T., Szczylik C., et al. Final results of the randomized phase III trial of sorafenib in advanced renal cell carcinoma: Survival and biomarker analysis//J Clin Oncol. 2007; 25:15s (suppl; abstr 5023).
  • McKiernan J.M., Buttyan R., Bander N.H., et al. The detection of renal carcinoma cells in the peripheral blood with an enhanced reverse transcriptase-polymerase chain reaction assay for MN/CA9//Cancer. 1999 Aug 1; 86(3):492-7.
  • Zhou G.X., Ireland J., Rayman P., Finke J., Zhou M. Quantification of carbonic anhydrase IX expression in serum and tissue of renal cell carcinoma patients using enzyme-linked immunosorbent assay: prognostic and diagnostic potentials//Urology. 2010 Feb 1; 75(2): 257-61.
  • Li G., Feng G., Gentil-Perret A., Genin C., Tostain J. Serum carbonic anhydrase 9 level is associated with postoperative 98 recurrence of conventional renal cell cancer//J Urol. 2008 Aug 1;180(2):510-3; discussion 3-4.
  • Gilbert S.M., Whitson J.M., Mansukhani M., et al. Detection of carbonic anhydrase-9 gene expression in peripheral blood cells predicts risk of disease recurrence in patients with renal cortical tumors//Urology. 2006 May 1; 67(5):942-5.
  • Atkins M., Regan M., McDermott D., et al. Carbonic anhydrase IX expression predicts outcome of interleukin 2 therapy for renal cancer//Clin Cancer Res. 2005; 11: 3714-3721.
  • Genega E.M., Ghebremichael M., Najarian R., et al. Carbonic anhydrase IX expression in renal neoplasms: Correlation with tumor type and grade//Am J Clin Pathol. 2010; 134: 873-879.
  • Chow T.F., Mankaruos M., Scorilas A., Youssef Y., Girgis A., Mossad S., Metias S., Rofael Y., Honey R.J., Stewart R., et al: The miR-17-92 cluster is overexpressed in, and has an oncogenic effect on, renal cell carcinoma//J Urol 2010, 183:743-751.
  • Neal C.S., Michael M.Z., Rawlings L.H., Van der Hoek M.B., Gleadle J.M. The VHL-dependent regulation of microRNAs in renal cell cancer//BMC Med 2010, 8:64.
  • Chen Z., Li Y., Zhang H., Huang P., Luthra R. Hypoxia-regulated microRNA-210 modulates mitochondrial function and decreases ISCU and COX10 expression//Oncogene 2010, 29:4362-4368.
  • Gonsalves C.S., Kalra V.K. Hypoxia-mediated expression of 5-lipoxygenaseactivating protein involves HIF-1alpha and NF-kappaB and microRNAs 135a and 199a-5p//J Immunol 2010, 184:3878-3888.
  • Muth M., Theophile K., Hussein K., Jacobi C., Kreipe H., Bock O. Hypoxiainduced down-regulation of microRNA-449a/b impairs control over targeted SERPINE1 (PAI-1) m//J Transl Med 2010, 8:33.
  • Liu H., Brannon A.R., Reddy A.R., Alexe G., Seiler M.W., Arreola A.,Oza J.H., Yao M., Juan D., Liou L.S., Ganesan S., Levine A.J., Rathmell W.K. and Bhanot G.V. Identifying mRNA targets of microRNA dysregulated in cancer: with application to clear cell Renal Cell Carcinoma//BMC Systems Biology 2010, 4:51; DOI: 10.1186/1752-0509-4-51
  • Mraz M., Pospisilova S., Malinova K., et al. MicroRNAs in chronic lymphocytic leukemia: pathogenesis and disease subtypes//Leuk Lymphoma. 2009 March; 50(3): 506-9.
  • Nielsen B.S., J0rgensen S., Fog J.U., S0kilde R., Christensen I.J., Hansen U., Brünner N., Baker A., M0ller S., Nielsen H.J. High levels of microRNA-21 in the stroma of colorectal cancers predict short disease-free survival in stage II colon cancer patients//Clin Exp Metastasis. 2010 Oct; 28(1): 27-38.
  • Nakada C., Matsuura K., Tsukamoto Y., Tanigawa M., Yoshimoto T., Narimatsu T., Nguyen L.T., Hijiya N., Uchida T., Sato F., Mimata H., Seto M., Moriyama M. Genome-wide microRNA expression profiling in renal cell carcinoma: significant down-regulation of miR-141 and miR-200c//J Pathol. 2008 Dec; 216(4): 418-27.
  • Gottardo F., Liu Ch.G., Ferracin M., Calin G.A., Fassan M., Bassi P., Sevignani C., Byrne D., Negrini M., Pagano F., Gomella L.G., M.D. Croce C.M., Baffa R. Micro-RNA profiling in kidney and bladder cancers//Urologic Oncology: Seminars and Original Investigations. 2007 Sept., V. 25 (5), P. 387-392.
  • Slaby O., Jancovicova J., Lakomy R., Svoboda M., Poprach A., Fabian P., Kren L., Michalek J., Vyzula R. Research Expression of miRNA-106b in conventional renal cell carcinoma is a potential marker for prediction of early metastasis after nephrectomy//Journal of Experimental & Clinical Cancer Research 2010, 29:90 http://www.jeccr. com/content/29/1/90.
  • Youssef Y.M., White N.M.A., Grigull J., Krizova A., Samy Ch., Mejia-Guerrero S., Evans A., Yousef G.M. Accurate Molecular Classification of Kidney Cancer Subtypes Using MicroRNA Signature//European Urology, 2011; Vol. 59 (5): e27-e32.
  • Volpe A., Mattar K., Finelli A., Kachura J.R., Evans A.J., Geddie W.R., Jewett M.A. Contemporary results of percutaneous biopsy of 100 small renal masses: a single center experience//J Urol. 2008, Vol.180(6), P. 2333-2337.
Еще
Статья
QR-код для установки приложения SciUp Наведите камеру и скачайте бесплатное приложение SciUp